Literature DB >> 22003224

Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.

Naomi Fujioka1, Julia Nguyen, Chunsheng Chen, Yunfang Li, Teena Pasrija, Gloria Niehans, Katherine N Johnson, Vinita Gupta, Robert A Kratzke, Kalpna Gupta.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) is coactivated by the μ-opioid receptor (MOR), expressed on non-small cell lung cancer (NSCLC) cells and human lung cancer. We hypothesized that clinically used opioid analgesics that are MOR agonists coactivate EGFR, resulting in growth- and survival-promoting signaling.
METHODS: We used H2009, a human adenocarcinoma NSCLC cell line, with constitutive EGFR phosphorylation, which showed increased expression of MOR and the δ-opioid receptor by reverse transcriptase polymerase chain reaction. We used Western immunoblotting, magnetic bead-based Bio-Plex cytokine assay, immunofluorescent staining, BrdU incorporation enzyme-linked immunosorbent assay, and BioCoat™ Matrigel™ invasion assay to examine cell signaling, cytokine expression, colocalization of MOR and EGFR in human lung cancer, and cell proliferation and invasion, respectively.
RESULTS: Similar to epidermal growth factor (EGF), morphine stimulated phosphorylation of EGFR, Akt/protein kinase B (Akt), and mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) signaling in H2009 cells. Opioid receptor (OR) antagonist, naloxone, EGFR tyrosine kinase inhibitor, erlotinib, and silencing of MOR and δ-opioid receptor abrogated morphine- and EGF-induced phosphorylation of signaling, suggestive of OR-mediated coactivation of EGFR. H2009 cells secreted significantly higher levels of cytokines compared with control Beas2B epithelial cells. H2009-conditioned medium stimulated MOR expression in Beas2B cells, suggesting that cytokines secreted by H2009 may be associated with increased OR expression in H2009. We observed colocalization of EGFR and MOR, in human NSCLC tissue. Functionally, morphine- and EGF-induced proliferation and invasion of H2009 cells was ameliorated by naloxone as well as erlotinib.
CONCLUSION: Morphine-induced phosphorylation of EGFR occurs via ORs, leading to downstream MAPK/ERK, Akt phosphorylation, cell proliferation, and increased invasion. Notably, ORs are also associated with EGF-induced phosphorylation of EGFR. Increased coexpression of MOR and EGFR in human lung cancer suggests that morphine may have a growth-promoting effect in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22003224      PMCID: PMC3725599          DOI: 10.1213/ANE.0b013e318232b35a

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  50 in total

1.  Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  David M Jackman; Beow Y Yeap; Lecia V Sequist; Neal Lindeman; Alison J Holmes; Victoria A Joshi; Daphne W Bell; Mark S Huberman; Balazs Halmos; Michael S Rabin; Daniel A Haber; Thomas J Lynch; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

2.  Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.

Authors:  P A Singleton; M W Lingen; M J Fekete; J G N Garcia; J Moss
Journal:  Microvasc Res       Date:  2006-07-03       Impact factor: 3.514

3.  Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation.

Authors:  Nabil El Zein; Stéphanie D'Hondt; Eric Sariban
Journal:  Cell Signal       Date:  2010-05-24       Impact factor: 4.315

4.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Claire Watkins; Angela Flannery; Gillian Ellison; Emma Donald; Lucy Knight; Dinah Parums; Nicholas Botwood; Brian Holloway
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.

Authors:  Patrick A Singleton; Joe G N Garcia; Jonathan Moss
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

6.  Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Authors:  George R Blumenschein; Ulrich Gatzemeier; Frank Fossella; David J Stewart; Lisa Cupit; Frank Cihon; James O'Leary; Martin Reck
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

7.  EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation.

Authors:  Yuejun Chen; Hui Long; Ziyan Wu; Xi Jiang; Lan Ma
Journal:  Mol Biol Cell       Date:  2008-05-07       Impact factor: 4.138

8.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

Authors:  Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

9.  Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling.

Authors:  Mariana M Belcheva; Yun Tan; Virginia M Heaton; Amy L Clark; Carmine J Coscia
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

10.  Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.

Authors:  Neelu Puri; Ravi Salgia
Journal:  J Carcinog       Date:  2008
View more
  45 in total

1.  Topical fentanyl stimulates healing of ischemic wounds in diabetic rats.

Authors:  Mihir Gupta; Tasneem Poonawala; Mariya Farooqui; Marna E Ericson; Kalpna Gupta
Journal:  J Diabetes       Date:  2015-01-15       Impact factor: 4.006

Review 2.  Could Perioperative Opioid Use Increase the Risk of Cancer Progression and Metastases?

Authors:  Anupam Aich; Pankaj Gupta; Kalpna Gupta
Journal:  Int Anesthesiol Clin       Date:  2016

3.  Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer.

Authors:  J Nguyen; K Luk; D Vang; W Soto; L Vincent; S Robiner; R Saavedra; Y Li; P Gupta; K Gupta
Journal:  Br J Anaesth       Date:  2014-05-26       Impact factor: 9.166

4.  Morphine inhibits cell viability and growth via suppression of vascular endothelial growth factor in human oral cancer HSC-3 cells.

Authors:  Tadashi Nishiwada; Yoshitaka Kawaraguchi; Keiko Uemura; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2019-05-02       Impact factor: 2.078

5.  Increased μ-opioid receptor expression in metastatic lung cancer.

Authors:  P A Singleton; T Mirzapoiazova; R Hasina; R Salgia; J Moss
Journal:  Br J Anaesth       Date:  2014-06-11       Impact factor: 9.166

6.  Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo.

Authors:  M L Weber; C Chen; Y Li; M Farooqui; J Nguyen; T Poonawala; R P Hebbel; K Gupta
Journal:  Br J Anaesth       Date:  2013-07-02       Impact factor: 9.166

Review 7.  [Interaction of anesthetics and analgesics with tumor cells].

Authors:  A Bundscherer; M Malsy; D Bitzinger; B M Graf
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

8.  The effects of anesthetics on tumor progression.

Authors:  Lifang Mao; Suizhen Lin; Jun Lin
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-03-08

Review 9.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

10.  Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.

Authors:  Dylan Zylla; Brett L Gourley; Derek Vang; Scott Jackson; Sonja Boatman; Bruce Lindgren; Michael A Kuskowski; Chap Le; Kalpna Gupta; Pankaj Gupta
Journal:  Cancer       Date:  2013-09-16       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.